Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Learn more about:
Related Clinical Trial
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter’s Syndrome ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL Phase 1 Study VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter’s Syndrome; Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter’s Transformation Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Allogeneic Stem Cell Transplant for CLL Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter’s Transformation Registry of the German CLL Study Group Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter’s Syndrome PNT2258 for Treatment of Patients With Richter’s Transformation (Brighton) Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter’s Transformation and Leukemias Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Study of Blinatumomab in Richter Transformation Genomic and Proteomic Study of Richter Syndrome (CGPSR) CRC043: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter’s Syndrome Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter’s Transformation or Richter’s Syndrome Patients Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter’s Syndrome A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter’s Syndrome Selinexor in Initial or Refractory and/or Relapsed Richter’s Transformation

Brief Title

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Official Title

Trial of Immune Reconstitution With Activated T-Cells in Patients With Chronic Lymphocytic Leukemia (CLL)

Brief Summary

      This phase II trial studies the side effects of ex vivo-activated autologous lymph node
      lymphocytes infusion and to see how well they work in treating patients with chronic
      lymphocytic leukemia. Biological therapies, such as ex vivo-activated autologous lymph node
      lymphocytes, use substances made from living organisms that may stimulate or suppress the
      immune system in different ways and stop tumor cells from growing.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To assess the feasibility and safety of infusion of autologous activated T-cells (ex
      vivo-activated autologous lymph node lymphocytes) in patients with chronic lymphocytic
      leukemia.

      SECONDARY OBJECTIVES:

      I. To study immune reconstitution following infusion of activated T-cells in patients with
      chronic lymphocytic leukemia.

      II. To study the incidence of infections for up to 1 year following activated T cell
      infusion.

      III. To study the overall response rates.

      OUTLINE:

      Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes
      intravenously (IV) over 10-30 minutes on day 0.

      Patients who have been previously treated on study, and subsequently need additional
      infusions, may be retreated with previously cryopreserved expanded cells at the same or lower
      dose level 6-12 months after the first infusion.

      After completion of study treatment, patients are followed up at 1.5 years and then every 6
      months for up to 5 years.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT.

Secondary Outcome

 Immune Reconstitution

Condition

Anemia

Intervention

Ex Vivo-activated Autologous Lymph Node Lymphocytes

Study Arms / Comparison Groups

 Treatment (ex vivo autologous lymph node lymphocytes)
Description:  Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

8

Start Date

December 18, 2015

Completion Date

April 30, 2018

Primary Completion Date

April 30, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  All patients must have a diagnosis of chronic lymphocytic leukemia (CLL) by
             immunophenotyping and flow cytometry analysis of blood or bone marrow

               -  Patients must meet criteria for treatment based on the criteria proposed by
                  National Cancer Institute (NCI)-sponsored CLL Working Group to include at least
                  one of the following:

                    -  Weight loss of more than 10% over the preceding 6 months; or

                    -  Extreme fatigue attributable to progressive disease; or

                    -  Fever or night sweats without evidence of infection; or

                    -  Worsening anemia (Rai stage Ill) or thrombocytopenia (Rai stage IV); or

                    -  Massive lymphadenopathy (> 10 cm) or rapidly progressive lymphocytosis
                       (lymphocyte doubling time < 6 months); or

                    -  Prolymphocytic or Richter's transformation; or

               -  Patients with CLL who have received at least one prior line of therapy; or

               -  Patients with CLL who have frequent infections and/or recurrent secondary cancers

          -  No active central nervous system (CNS) disease

          -  All patients must have a Karnofsky performance score > 60%

          -  Calculated creatinine clearance (by Cockcroft-Gault) of > 50 ml/min

          -  Patients must not have untreated or uncontrolled life-threatening infection

          -  Patients must sign informed consent

        Exclusion Criteria:

          -  Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for
             the use of allergic rhinitis or pulmonary disease) within 2 weeks of registration

          -  Autoimmune disease related to CLL, e.g., idiopathic thrombocytopenic purpura (ITP) or
             autoimmune hemolytic anemia, is permitted if not requiring active treatment
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Chitra Hosing, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02530515

Organization ID

2014-0830

Secondary IDs

NCI-2015-01546

Responsible Party

Sponsor

Study Sponsor

M.D. Anderson Cancer Center

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Chitra Hosing, Principal Investigator, M.D. Anderson Cancer Center


Verification Date

October 2019